Floatz logo

Mebendazole

Brain Stem Neoplasms, Malignant

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Brain Stem Neoplasms, Malignant cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Julie Krystal
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 1/2B
Valproic Acid
Baylor College of Medicine
Phase 2B

View all 32 →

Same molecule, other indications

Mebendazole is also rated in:

Overall SurvivalDormant
B
Indicative ·
60 / 100
View asset →
anaplastic astrocytomaDormant
B
Indicative ·
57 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →